Scientific Background and Reference Sources
Abej, E., El-Matary, W., Singh, H., & Bernstein, C. N. (2016). The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol, 2016, 2483261. https://doi.org/10.1155/2016/2483261
Almario, C. V., Ballal, M. L., Chey, W. D., Nordstrom, C., Khanna, D., & Spiegel, B. M. R. (2018). Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. Am J Gastroenterol, 113(11), 1701-1710. https://doi.org/10.1038/s41395-018-0256-8
Boirivant, M., & Cossu, A. (2012). Inflammatory bowel disease. Oral Dis, 18(1), 1-15. https://doi.org/10.1111/j.1601-0825.2011.01811.x
Burri, E., & Beglinger, C. (2014). The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol, 8(2), 197-210. https://doi.org/10.1586/17474124.2014.869476
Campbell, J. P., Zierold, C., Rode, A. M., Blocki, F. A., & Vaughn, B. P. (2021). Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. J Clin Gastroenterol, 55(3), 239-243. https://doi.org/10.1097/mcg.0000000000001359
Colombel, J. F., Shin, A., & Gibson, P. R. (2019). AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol, 17(3), 380-390.e381. https://doi.org/10.1016/j.cgh.2018.08.001
Fagerhol, M. K., Dale, I., & Andersson, T. (1980). A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir, 16 Suppl, 273-282.
FDA. (2006). 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION https://www.accessdata.fda.gov/cdrh_docs/reviews/K050007.pdf
FDA. (2016). 510(k) https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160447.pdf
FDA. (2018a). 510(k) https://www.accessdata.fda.gov/cdrh_docs/pdf18/K182698.pdf
FDA. (2018b). LIAISON Calprotectin. https://www.accessdata.fda.gov/cdrh_docs/pdf18/K182698.pdf
FDA. (2019). Buhlmann FCAL Turbo And CALEX Cap. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K191718
Gibson, P. (2022). Irritable bowel syndrome in patients with inflammatory bowel disease - UpToDate. https://www.uptodate.com/contents/irritable-bowel-syndrome-in-patients-with-inflammatory-bowel-disease
Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J. O., Peyrin-Biroulet, L., Cullen, G. J., Daperno, M., Kucharzik, T., Rieder, F., Almer, S., Armuzzi, A., Harbord, M., Langhorst, J., Sans, M., Chowers, Y., Fiorino, G., Juillerat, P., . . . on behalf of, E. (2016). 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis, 11(1), 3-25. https://doi.org/10.1093/ecco-jcc/jjw168
Halpin, S. J., & Ford, A. C. (2012). Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol, 107(10), 1474-1482. https://doi.org/10.1038/ajg.2012.260
Higuchi, L. M., & Bousvaros, A. (2024). Clinical presentation and diagnosis of inflammatory bowel disease in children - UpToDate. In M. Heyman (Ed.), UpToDate. https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-inflammatory-bowel-disease-in-children
Hsu, K., Champaiboon, C., Guenther, B. D., Sorenson, B. S., Khammanivong, A., Ross, K. F., Geczy, C. L., & Herzberg, M. C. (2009). ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS. Antiinflamm Antiallergy Agents Med Chem, 8(4), 290-305. https://doi.org/10.2174/187152309789838975
Johnson, L. M., Spannagl, M., Wojtalewicz, N., & Durner, J. (2022). Comparison of fecal calprotectin and pancreatic elastase assays based on proficiency testing results. Clin Biochem, 107, 19-23. https://doi.org/10.1016/j.clinbiochem.2022.05.002
Khaki-Khatibi, F., Qujeq, D., Kashifard, M., Moein, S., Maniati, M., & Vaghari-Tabari, M. (2020). Calprotectin in inflammatory bowel disease. Clin Chim Acta, 510, 556-565. https://doi.org/10.1016/j.cca.2020.08.025
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol, 116(1), 17-44. https://doi.org/10.14309/ajg.0000000000001036
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018). ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol, 113(4), 481-517. https://doi.org/10.1038/ajg.2018.27
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., Burisch, J., Castiglione, F., Eliakim, R., Ellul, P., González-Lama, Y., Gordon, H., Halligan, S., Katsanos, K., Kopylov, U., . . . Stoker, J. (2019). ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis, 13(2), 144-164. https://doi.org/10.1093/ecco-jcc/jjy113
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., Langner, C., Limdi, J. K., Pellino, G., Zagórowicz, E., Raine, T., Harbord, M., Rieder, F., for the European, C. s., & Colitis, O. (2017). Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 11(6), 649-670. https://doi.org/10.1093/ecco-jcc/jjx008
Mao, R., Xiao, Y. L., Gao, X., Chen, B. L., He, Y., Yang, L., Hu, P. J., & Chen, M. H. (2012). Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis, 18(10), 1894-1899. https://doi.org/10.1002/ibd.22861
Molander, P., af Bjorkesten, C. G., Mustonen, H., Haapamaki, J., Vauhkonen, M., Kolho, K. L., Farkkila, M., & Sipponen, T. (2012). Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis, 18(11), 2011-2017. https://doi.org/10.1002/ibd.22863
Molander, P., Farkkila, M., Ristimaki, A., Salminen, K., Kemppainen, H., Blomster, T., Koskela, R., Jussila, A., Rautiainen, H., Nissinen, M., Haapamaki, J., Arkkila, P., Nieminen, U., Kuisma, J., Punkkinen, J., Kolho, K. L., Mustonen, H., & Sipponen, T. (2015). Does fecal calprotectin predict short-term relapse after stopping TNFalpha-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis, 9(1), 33-40. https://doi.org/10.1016/j.crohns.2014.06.012
Mumolo, M. G., Bertani, L., Ceccarelli, L., Laino, G., Di Fluri, G., Albano, E., Tapete, G., & Costa, F. (2018). From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol, 24(33), 3681-3694. https://doi.org/10.3748/wjg.v24.i33.3681
NICE. (2017). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel DG11. NICE Diagnostics guidance. https://www.nice.org.uk/guidance/DG11
Rosenfeld, G., Greenup, A. J., Round, A., Takach, O., Halparin, L., Saadeddin, A., Ho, J. K., Lee, T., Enns, R., & Bressler, B. (2016). FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol, 22(36), 8211-8218. https://doi.org/10.3748/wjg.v22.i36.8211
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol, 114(3), 384-413. https://doi.org/10.14309/ajg.0000000000000152
Singh, S., Ananthakrishnan, A. N., Nguyen, N. H., Cohen, B. L., Velayos, F. S., Weiss, J. M., Sultan, S., Siddique, S. M., Adler, J., & Chachu, K. A. (2023). AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology, 164(3), 344-372. https://doi.org/10.1053/j.gastro.2022.12.007
Tham, Y. S., Yung, D. E., Fay, S., Yamamoto, T., Ben-Horin, S., Eliakim, R., Koulaouzidis, A., & Kopylov, U. (2018). Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. Therap Adv Gastroenterol, 11, 1756284818785571. https://doi.org/10.1177/1756284818785571
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I., & Bjarnason, I. (2002). Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology, 123(2), 450-460. https://doi.org/10.1053/gast.2002.34755
van Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010). Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Bmj, 341, c3369. https://doi.org/10.1136/bmj.c3369
von Roon, A. C., Karamountzos, L., Purkayastha, S., Reese, G. E., Darzi, A. W., Teare, J. P., Paraskeva, P., & Tekkis, P. P. (2007). Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol, 102(4), 803-813. https://doi.org/10.1111/j.1572-0241.2007.01126.x
Walsham, N. E., & Sherwood, R. A. (2016). Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol, 9, 21-29. https://doi.org/10.2147/ceg.s51902
Waugh, N., Cummins, E., Royle, P., Kandala, N. B., Shyangdan, D., Arasaradnam, R., Clar, C., & Johnston, R. (2013). Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess, 17(55), xv-xix, 1-211. https://doi.org/10.3310/hta17550
Yang, Z., Clark, N., & Park, K. T. (2014). Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol, 12(2), 253-262.e252. https://doi.org/10.1016/j.cgh.2013.06.028
Specialty Matched Consultant Advisory Panel review 11/2019
Medical Director review 11/2019
Specialty Matched Consultant Advisory Panel review 11/2020
Medical Director review 11/2020
Specialty Matched Consultant Advisory Panel review 11/2021
Medical Director review 11/2021
Medical Director review 11/2022
Medical Director review 11/2023
Medical Director review 10/2024